Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
Readout of the delayed Galaxies Lung-201 study is due imminently.